Kezar Life Sciences’ (KZR) Neutral Rating Reaffirmed at HC Wainwright

Kezar Life Sciences (NASDAQ:KZR)‘s stock had its “neutral” rating reaffirmed by analysts at HC Wainwright in a research report issued to clients and investors on Monday,Benzinga reports.

Several other equities research analysts have also recently weighed in on KZR. William Blair reiterated a “market perform” rating on shares of Kezar Life Sciences in a research report on Wednesday, November 13th. Wells Fargo & Company lowered their target price on shares of Kezar Life Sciences from $20.00 to $11.00 and set an “equal weight” rating on the stock in a research note on Thursday, November 14th.

Kezar Life Sciences Stock Performance

Shares of KZR stock opened at $7.47 on Monday. Kezar Life Sciences has a 12 month low of $5.20 and a 12 month high of $11.35. The stock has a market capitalization of $54.53 million, a P/E ratio of -0.57 and a beta of 0.22. The company has a current ratio of 7.65, a quick ratio of 7.65 and a debt-to-equity ratio of 0.05. The firm’s 50 day moving average is $7.55 and its 200 day moving average is $6.78.

Kezar Life Sciences (NASDAQ:KZR) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($2.78) EPS for the quarter, topping analysts’ consensus estimates of ($3.03) by $0.25. On average, sell-side analysts anticipate that Kezar Life Sciences will post -6.3 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. XTX Topco Ltd lifted its position in Kezar Life Sciences by 256.1% during the third quarter. XTX Topco Ltd now owns 52,148 shares of the company’s stock valued at $40,000 after purchasing an additional 37,504 shares during the last quarter. Mackenzie Financial Corp bought a new stake in shares of Kezar Life Sciences during the 2nd quarter worth $35,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in Kezar Life Sciences in the second quarter worth $63,000. Geode Capital Management LLC raised its position in Kezar Life Sciences by 15.0% during the third quarter. Geode Capital Management LLC now owns 626,912 shares of the company’s stock valued at $485,000 after purchasing an additional 81,678 shares in the last quarter. Finally, Acuitas Investments LLC lifted its stake in Kezar Life Sciences by 42.8% during the second quarter. Acuitas Investments LLC now owns 986,785 shares of the company’s stock worth $592,000 after purchasing an additional 295,956 shares during the last quarter. 67.90% of the stock is currently owned by institutional investors.

About Kezar Life Sciences

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.